Research programme: antisense oligonucleotide therapeutics - Denali Therapeutics/Secarna Pharmaceuticals
Alternative Names: OTV CH2; OTV LF3Latest Information Update: 28 Feb 2025
At a glance
- Originator Denali Therapeutics Inc; Secarna Pharmaceuticals
- Class Antidementias; Antiparkinsonians; Antisense oligonucleotides
- Mechanism of Action Gene silencing
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders; Neurodegenerative disorders
- No development reported Alzheimer's disease; Parkinson's disease
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for research development in Alzheimer's-disease in Germany (IV)
- 28 Feb 2025 No recent reports of development identified for research development in Alzheimer's-disease in USA (IV)
- 28 Feb 2025 No recent reports of development identified for research development in Parkinson's-disease in Germany (IV)